Here at MS Money Moves, we seek to provide the research edge that retail investors need in order to be successful in these volatile markets. One thing we know in the world of investing in … [Read more...] about Reader’s Choice: New Institutional Buys 1Q2020
Articles
LJPC and BCRX Updates: 5/27/20
5/27/20 was the worst day for our team since March 13th when almost every stock on the market was halted due to volatility. Our two largest positions, La Jolla Pharmaceuticals (Nasdaq: LJPC) and … [Read more...] about LJPC and BCRX Updates: 5/27/20
The Next Approval for Epizyme (NASDAQ: EPZM)
It has been approximately three months since I previously broke the story on Epizyme's (EPZM) tazemetostat after its initial approval for metastatic or locally advanced epithelioid sarcoma not … [Read more...] about The Next Approval for Epizyme (NASDAQ: EPZM)
Zynerba Pharmaceuticals (NASDAQ: ZYNE): An Overlooked Gem
When I say marijuana in the context of the stock market, you probably immediately think "pot stocks" and the likes of Cronos Group, Canopy Growth Corporation, and Aurora Cannabis. Some of you … [Read more...] about Zynerba Pharmaceuticals (NASDAQ: ZYNE): An Overlooked Gem
DelMar Pharmaceutical (NASDAQ: DMPI) Remains On Track Despite COVID-19 Crisis
Recap: Since November of 2019 MS Money Moves has been following DelMar Pharmaceuticals (Nasdaq: DMPI) closely through a number of key value inflection points. In my initial article I … [Read more...] about DelMar Pharmaceutical (NASDAQ: DMPI) Remains On Track Despite COVID-19 Crisis
ASCO 2020 Guide
As we move from spring to summer, we enter the season of several prominent medical conferences, the first of which will be the annual American Society of Clinical Oncology (ASCO) conference. With the … [Read more...] about ASCO 2020 Guide
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish